Viking Therapeutics (VKTX) Cash from Financing Activities (2014 - 2026)

Viking Therapeutics has disclosed Cash from Financing Activities across 13 years of filings, most recently posting $12.1 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $12.1 million, up 3360.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.2 million (up 1201.17% YoY), and the FY2025 annual result was $76.4 million, down 87.52% from the prior year.
• Cash from Financing Activities came in at $12.1 million for Q1 2026 at Viking Therapeutics, down from $75.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $606.0 million in Q1 2024 to a low of -$5.0 million in Q1 2022.
• The 5-year median for Cash from Financing Activities is $1.0 million (2024), against an average of $57.4 million.
• Across the five-year window, Cash from Financing Activities surged 22770.21% in 2022 and plunged 840.0% in 2023, its largest moves.
• Viking Therapeutics' Cash from Financing Activities stood at $10.7 million in 2022, then sank by 98.25% to $188000.0 in 2023, then soared by 431.91% to $1.0 million in 2024, then surged by 7410.3% to $75.1 million in 2025, then sank by 83.92% to $12.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $12.1 million (Q1 2026), $75.1 million (Q4 2025), and $480000.0 (Q3 2025), per Business Quant data.